论文部分内容阅读
目的 观察丝裂霉素、异环磷酰胺和顺铂组成的ＭＩＰ方案治疗晚期非小细胞肺癌的近期疗效、耐受性和生存期。方法 ５６例晚期非小细胞肺癌接受ＭＩＰ方案治疗。结果 可评价疗效病例５６例，总有效率４６．４％，中位缓解期８个月，中位生存期９．６个月，１年生存率３５．０％。主要毒副作用为骨髓抑制。结论 ＭＩＰ联合化疗方案对晚期非小细胞肺癌有较好疗效，毒副作用可耐受。
Objective To observe the short-term efficacy, tolerability and survival of MIP regimen consisting of mitomycin, ifosfamide and cisplatin in the treatment of advanced non-small cell lung cancer. Methods 56 cases of advanced non-small cell lung cancer were treated with MIP regimen. Results 56 cases were evaluated for curative effect, the total effective rate was 46.4%, the median remission was 8 months, the median survival time was 9.6 months, and the 1-year survival rate was 35.0%. The main side effects of bone marrow suppression. Conclusions MIP combined with chemotherapy has good curative effect on advanced non-small cell lung cancer with tolerable side effects.